tbuckley/cabot-search huggingface dataset:
Biology of IDH mutant cholangiocarcinoma
Authors: Meng‐Ju Wu, Lei Shi, Joshua Merritt, Andrew X. Zhu, Nabeel Bardeesy
Journal: Hepatology (2022)

Abstract Isocitrate dehydrogenase 1 and 2 ( IDH1 and IDH2 ) are the most frequently mutated metabolic genes across human cancers. These hotspot gain‐of‐function mutations cause the IDH enzyme to aberrantly generate high levels of the oncometabolite, R‐2‐hydroxyglutarate, which competitively inhibits enzymes that regulate epigenetics, DNA repair, metabolism, and other processes. Among epithelial malignancies, IDH mutations are particularly common in intrahepatic cholangiocarcinoma (iCCA). Importantly, pharmacological inhibition of mutant IDH (mIDH) 1 delays progression of mIDH1 iCCA, indicating a role for this oncogene in tumor maintenance. However, not all patients receive clinical benefit, and those who do typically show stable disease rather than significant tumor regressions. The elucidation of the oncogenic functions of mIDH is needed to inform strategies that can more effectively harness mIDH as a therapeutic target. This review will discuss the biology of mIDH iCCA, including roles of mIDH in blocking cell differentiation programs and suppressing antitumor immunity, and the potential relevance of these effects to mIDH1‐targeted therapy. We also cover opportunities for synthetic lethal therapeutic interactions that harness the altered cell state provoked by mIDH1 rather than inhibiting the mutant enzyme. Finally, we highlight key outstanding questions in the biology of this fascinating and incompletely understood oncogene.
Erratum: Volume 21, Number 1, July 1958
Journal: JNCI Journal of the National Cancer Institute (1959)

Erratum: Volume 21, Number 1, July 1958 Get access JNCI: Journal of the National Cancer Institute, Volume 22, Issue 5, May 1959, Page 1025, https://doi.org/10.1093/jnci/22.5.1025 Published: 01 May 1959
Bodies
Authors: James Owen Drife
Journal: BMJ (2004)

BBC 3, Sundays at 9 pm from 23 May Rating: ![Graphic][1]</img>![Graphic][2]</img> Doctors who write fiction are few and far between. This is just as well. The two jobs do not go well together. Chekhov, Maugham, and Conan Doyle practised for a while and then left medicine behind to write about other things. Today it seems harder to let go. The modern medical author writes about doctors, not patients, and starts with juniors. Many of us found the early years traumatic and coped by developing a veneer of cynicism. This phase came to a natural end if we … [1]: /embed/inline-graphic-1.gif [2]: /embed/inline-graphic-2.gif
Relative Effects of Enterically Administered and Packed Cells on Circulating Blood Ammonia
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Manuscripts approved for JNCI, July–August 1975
Journal: JNCI Journal of the National Cancer Institute (1975)

Manuscripts approved for JNCI, July–August 1975 Get access JNCI: Journal of the National Cancer Institute, Volume 55, Issue 3, September 1975, Pages 739–741, https://doi.org/10.1093/jnci/55.3.739 Published: 01 September 1975
Medicolegal
Journal: JAMA (1906)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Changes in the societal burden caused by sleep apnoea in Finland from 1996 to 2018: A national registry study
Authors: Tiina Mattila, Hannele Hasala, Hanna-Riikka Kreivi, Heidi Avellan-Hietanen, Adel Bachour, Fredrik Herse, Riikka-Leena Leskelä, Sanna Toppila-Salmi, Marina Erhola, Tari Haahtela, Tuula Vasankari
Journal: The Lancet Regional Health - Europe (2022)

In the current century, sleep apnoea has become a significant public health problem due to the obesity epidemic. To increase awareness, improve diagnostics, and improve treatment, Finland implemented a national sleep apnoea programme from 2002 to 2010. Here, we present changes in the societal burden caused by sleep apnoea from 1996 to 2018.National register data were collected from the Care Register for Health Care, Statistics Finland, the Social Insurance Institution of Finland, and the Finnish Centre for Pensions. Disease prevalence, use of healthcare and social services, and societal costs were estimated.The number of sleep apnoea patients increased in secondary care from 8 600 in 1996 to 61 000 in 2018. There was a continuous increase in outpatient visits in secondary care from 9 700 in 1996 to 122 000 in 2018 (1 160%) and in primary care from 10 000 in 2015 to 29 000 in 2018 (190%). Accordingly, the cumulative annual number of days off work for sleep apnoea increased from 1 100 to 46 000. However, disability pensions for sleep apnoea decreased from 820 to 550 (33%) during the observation period. Societal costs per patient decreased over 50% during the observation period (€2 800 to €1 200).The number of sleep apnoea patients in Finland increased remarkably during the observation period. To control this burden, diagnostic methods and treatment were revised and follow up was reorganised. Consequently, there was a significant decrease in societal costs per patient. The decrease in disability pensions suggests earlier diagnosis and improved treatment. The national sleep apnoea programme was one of the initiators for these improved outcomes.The Finnish Institute for Health and Welfare and the Hospital District of Helsinki and Uusimaa (HUH), Helsinki, Finland.
Smoking-Attributable Cancer Mortality
Authors: EDWARD J. SONDIK
Journal: JNCI Journal of the National Cancer Institute (1991)

Smoking-Attributable Cancer Mortality Get access EDWARD J. SONDIK EDWARD J. SONDIK Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 83, Issue 24, 18 December 1991, Page 1834, https://doi.org/10.1093/jnci/83.24.1834 Published: 18 December 1991
INFECTION AND RICKETS
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Group 1 ILCs regulate T cell–mediated liver immunopathology by controlling local IL-2 availability
Authors: Valeria Fumagalli, Valentina Venzin, Pietro Di Lucia, Federica Moalli, Xenia Ficht, Gioia Ambrosi, Leonardo Giustini, Francesco Andreata, Marta Grillo, Diletta Magini, Micol Ravà, Christin Friedrich, Jason D. Fontenot, Philippe Bousso, Sarah A. Gilmore, Shahzada Khan, Manuel Baca, Eric Vivier, Georg Gasteiger, Mirela Kuka, Luca G. Guidotti, Matteo Iannacone
Journal: Science Immunology (2022)

Group 1 innate lymphoid cells (ILCs), which comprise both natural killer (NK) cells and ILC1s, are important innate effectors that can also positively and negatively influence adaptive immune responses. The latter function is generally ascribed to the ability of NK cells to recognize and kill activated T cells. Here, we used multiphoton intravital microscopy in mouse models of hepatitis B to study the intrahepatic behavior of group 1 ILCs and their cross-talk with hepatitis B virus (HBV)–specific CD8 + T cells. We found that hepatocellular antigen recognition by effector CD8 + T cells triggered a prominent increase in the number of hepatic NK cells and ILC1s. Group 1 ILCs colocalized and engaged in prolonged interactions with effector CD8 + T cells undergoing hepatocellular antigen recognition; however, they did not induce T cell apoptosis. Rather, group 1 ILCs constrained CD8 + T cell proliferation by controlling local interleukin-2 (IL-2) availability. Accordingly, group 1 ILC depletion, or genetic removal of their IL-2 receptor a chain, considerably increased the number of intrahepatic HBV-specific effector CD8 + T cells and the attendant immunopathology. Together, these results reveal a role for group 1 ILCs in controlling T cell–mediated liver immunopathology by limiting local IL-2 concentration and have implications for the treatment of chronic HBV infection.
AMA policy for testing HIV
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Commentaire de travail de J. van Hooft et al., pp. 434
Journal: Endoscopy (2007)

See also: First data on the palliative treatment of patients with malignant gastric outlet obstruction using the WallFlex enteral stent: a retrospective multicenter studyEndoscopy 2007; 39(05): 434-439DOI: 10.1055/s-2007-966338
Identifying Patients With Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma by Plasma Epstein-Barr Virus DNA for Chemotherapy Deintensification: <i>Quo Vadis</i>?
Authors: Wai-Tong Ng, Melvin L.K. Chua, Anne W.M. Lee
Journal: Journal of Clinical Oncology (2022)
Erratum
Authors: -C Slhould, Edward Fox
Journal: BMJ (1891)

distinction in special subjects shall be no longer awarded in connec- tion witlh the Seconid anid Finial Exaiminations for the Degrees of M.B. and Ch.B.That aftcr October 1st, PsW1, candidates whlo lhave satisfied the Ex- aminers in the Final Exanilnation for the Degrees of AMB. and Ch.B. shall be classed as follows: 1. 'I'lTose awarded first class honours.2. Those awarded second class lioinours.3.Those wlho have satisfied the ex- aminers.The niames bcing in alphabetical order in each case.That in the awardof honorus thie resuilts of thie Second as well as the Final Ex- amination slhall be taken inito account.
Therapy Approved for All Types of Severe Asthma
Authors: Howard D. Larkin
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Severe Malnutrition Among Young Children—Georgia, January 1997–June 1999
Journal: JAMA (2001)

In October 1999, the Georgia Department of Human Resources (GDHR) was notified of two cases of severe malnutrition in toddlers. Both cases were associated with the use of commercial alternative milk. In response, GDHR and CDC reviewed Georgia hospital records to assess the frequency and cause of hospitalized cases of rickets and protein energy malnutrition (PEM). The findings of this review indicated that, although no new cases were associated with milk alternatives, three children had PEM and six had vitamin D deficiency rickets. The children with rickets had been breast fed for approximately 6 months while receiving no vitamin D supplementation. Rickets is preventable through the adequate intake of vitamin D. The American Academy of Pediatrics (AAP) is examining vitamin D supplementation among breast-fed infants.
THE DISTRIBUTION OF ACETONE IN THE BODY
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Book Review The Injured Back and Its Treatment . Edited by John D. Ellis, M.D. Contributing authors: H. Earle Conwell, M.D., Loyal Davis, M.D., Nathan S. Davis, III, M.D., John D. Ellis, M.D., Ralph K. Ghormley, M.D., Hale A. Haven, M.D., Professor Sir Arthur Keith, F.R.C.S., F.R.S., and Robert B. Osgood, M.D. 4°, cloth, 377 pp., with 156 illustrations and 3 tables. Springfield, Illinois: Charles C Thomas, 1940. $5.50.
Journal: New England Journal of Medicine (1941)
Secondary Anetoderma
Authors: Myrian de Faria Melo, Isabela de Faria Melo, Gabriela Fortes Escobar
Journal: JAMA Dermatology (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Neurological Surgery
Authors: Benjamin S. Carson
Journal: JAMA (1990)

Neurosurgery has rapidly evolved into a very high-tech specialty. Neuroimaging modalities and neurophysiological monitoring techniques have eliminated a significant amount of postulation and have provided a sound basis for sophisticated preoperative planning. A small nonprioritized sampling of some of these technological advances would include the following: (1) transcranial Doppler ultrasonography, used in the diagnosis and treatment of a variety of conditions where assessment of intracranial arterial blood flow is important, (2) single-photon emission computed tomography, useful in the evaluation of cerebral hemodynamics, cerebral perfusion, and brain tumor permeability, (3) positron emission tomography, which quantitates metabolic activity and finds new applications every year, and (4) three-dimensional computed tomography, which enhances preoperative planning in cases of craniofacial reconstruction, and recently, in addition to computer software that readily permits mixing of different tissue-density signals, has provided three-dimensional visualization of complex skull base lesions and their relationship to bone and large vessels.<sup>1</sup>Magnetic
MEDICAL CHARITY ABUSE IN ENGLAND—AND ELSEWHERE.
Journal: JAMA (1896)

At last the British lay public is becoming aroused to the existence of what an editorial writer in<i>The Saturday Review</i>justly calls "an intolerable national scandal"—namely, the abuse of medical charities, and such being the case, we may hope for some abatement of the evil. From or through the medical profession we may apparently hope little or nothing at all. There are a hundred reasons for this, many of which have often enough been iterated and reiterated, and the fact is deplorable—but fact it is. It is true that there is a committee of the British Medical Association on medical charities, and the last report of its subcommittee through its chairman, Mr.Thomas Bridgwater, concerning certain London hospitals (<i>Brit. Med. Jour.</i>, July 18, 1896, p. 139) is interesting reading—interesting from the positive proof it gives of the failure of "Reform within the Party," and also from the indirect evidence
The Parallel Transformations of Polycyclic Aromatic Hydrocarbons in the Body and in the Atmosphere
Authors: Amy I.H. Hrdina, Ishwar N. Kohale, Simran Kaushal, Jamie Kelly, Noelle E. Selin, Bevin P. Engelward, Jesse H. Kroll
Journal: Environmental Health Perspectives (2022)

Polycyclic aromatic hydrocarbons (PAHs) emitted from combustion sources are known to be mutagenic, with more potent species also being carcinogenic. Previous studies show that PAHs can undergo complex transformations both in the body and in the atmosphere, yet these transformation processes are generally investigated separately.Drawing from the literature in atmospheric chemistry and toxicology, we highlight the parallel transformations of PAHs that occur in the atmosphere and the body and discuss implications for public health. We also examine key uncertainties related to the toxicity of atmospheric oxidation products of PAHs and explore critical areas for future research.We focus on a key mode of toxicity for PAHs, in which metabolic processes (driven by cytochrome P450 enzymes), leads to the formation of oxidized PAHs that can damage DNA. Such species can also be formed abiotically in the atmosphere from natural oxidation processes, potentially augmenting PAH toxicity by skipping the necessary metabolic steps that activate their mutagenicity. Despite the large body of literature related to these two general pathways, the extent to which atmospheric oxidation affects a PAH's overall toxicity remains highly uncertain. Combining knowledge and promoting collaboration across both fields can help identify key oxidation pathways and the resulting products that impact public health.Cross-disciplinary research, in which toxicology studies evaluate atmospheric oxidation products and their mixtures, and atmospheric measurements examine the formation of compounds that are known to be most toxic. Close collaboration between research communities can help narrow down which PAHs, and which PAH degradation products, should be targeted when assessing public health risks. https://doi.org/10.1289/EHP9984.